Quantum BioPharma's Anthony Durkacz joins MarketBeat's Bridget Bennett to break down the FDA approval process and what investors need to know before buying biotech stocks. AI is speeding up drug discovery, but every drug still has to get through the same hoops, and most never make it. In this interview, you'll hear what happens in phase 1, phase 2, and phase 3 clinical trials, why Anthony says most of the value tends to build after phase 2 data, when big pharma usually steps in, and how funding and dilution can make or break a small biotech company. He also shares an update on his company's phase 2 trial for multiple sclerosis, and he stresses that biotech carries a tremendous amount of risk. FDA approval process, how to invest in biotech stocks, biotech stocks to buy now, clinical trial phases explained, phase 2 biotech stocks, AI biotech stocks, multiple sclerosis treatment, and what investors need to know about drug trials, all in this stock market update.
Disseminated on behalf of Quantum BioPharma (NASDAQ:QNTM).
Read the full report: https://tomorrowinvestor.com/quantum-biopharma-new-breakthrough-treatment-for-multiple-sclerosis/
Learn more at the company website: https://www.quantumbiopharma.com/investors
Disclosure/Disclaimer: We are not securities dealers or brokers, investment advisers or financial advisers, and you should not rely on the information herein as investment advice. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. This video was conducted on behalf of Quantum BioPharma and was funded by Think Ink Marketing. For our full disclaimer, please visit: https://tomorrowinvestor.com/quantum-biopharma-new-breakthrough-treatment-for-multiple-sclerosis/#disclaimer
Bridget Bennett, Host
Digital Media Producer, MarketBeat
Always the talker, Bridget Bennett turned her passion for people and sharing stories into a career in communications. She started working as a journalist in high school at her local county paper in Ellendale, North Dakota. After moving to Dallas for college at Southern Methodist University, she quickly fell in love with visual storytelling and started her career as a news anchor and reporter.
Bridget brings her 12 years of experience in broadcast writing and video production to the MarketBeat content team. She's also an energetic, creative thinker and lifelong learner, so she's always bringing new ideas. Bridget is thrilled to be part of an innovative team that is constantly looking to create useful content people can connect with.
When she's not working, Bridget is a busy mom of three and can be found at just about every activity or outing in town. She is also an adoption and foster care advocate and helps support foster children and families through her nonprofit volunteer work. She and her husband, Jason, grew up together and have spent their lives exploring the world through travel, hiking and ministry.
Anthony Durkacz, Guest
Co-Founder, Executive Co-Chairman of the Board, Quantum BioPharma
Anthony Durkacz is the Co-Founder and Executive Co-Chairman of Quantum BioPharma (NASDAQ: QNTM). He has a background spanning capital markets, corporate finance, investor relations, M&A, and public-company management.
He began his career on the TD Securities capital-markets trading floor. He later served as CFO and director of Astris Energi, a U.S.- and Canadian-listed alternative-energy company that was ultimately acquired; COO and CFO of MKU Canada, where he worked on international M&A; and CFO/director of Snipp Interactive, where he played a role in financing and taking the company public. He subsequently served as President of Capital Ideas Investor Relations.
Since 2014, Durkacz has also served as a director and Executive Vice President of First Republic Capital Corporation, a Canadian exempt-market dealer involved in micro-cap financing. He has additionally served as Chairman and CEO of Stock Trend Capital.
Durkacz became a director of what is now Quantum BioPharma in June 2018 and has served as Executive Co-Chairman since May 2021. He also served as the company’s interim CEO from July 2021 until July 2023, when co-founder Zeeshan Saeed became CEO.
He holds an Honours Bachelor of Business Administration from Brock University, with majors in Accounting and Finance.
